<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">EJNMMI Rep</journal-id><journal-id journal-id-type="iso-abbrev">EJNMMI Rep</journal-id><journal-title-group><journal-title>EJNMMI Reports</journal-title></journal-title-group><issn pub-type="epub">3005-074X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39890711</article-id><article-id pub-id-type="pmc">PMC11785851</article-id><article-id pub-id-type="publisher-id">238</article-id><article-id pub-id-type="doi">10.1186/s41824-025-00238-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Impact of delayed pelvic imaging on the staging of biochemical recurrence in prostate cancer patients using [<sup>18</sup>F]DCFPYL PET/CT: a retrospective evaluation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0009-0002-1219-1847</contrib-id><name><surname>Rodr&#x000ed;guez-Pajuelo</surname><given-names>Ana</given-names></name><address><email>anarodriguezp1511@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Guerra-G&#x000f3;mez</surname><given-names>Miriam</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Cuenca Cuenca</surname><given-names>Juan Ignacio</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Freire-Mac&#x000ed;as</surname><given-names>Jos&#x000e9; Mar&#x000ed;a</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Jim&#x000e9;nez-Hoyuela Garc&#x000ed;a</surname><given-names>Jos&#x000e9; Manuel</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>&#x000c1;lvarez-P&#x000e9;rez</surname><given-names>Rosa Mar&#x000ed;a</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Nuclear Medicine Department, University Hospital Virgen del Roc&#x000ed;o, Seville, USA </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>9</volume><issue>1</issue><elocation-id>5</elocation-id><history><date date-type="received"><day>2</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>3</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">The aim of this study was to evaluate the added diagnostic value of additional second stage pelvic scanning as part of the [<sup>18</sup>F]DCFPYL PET/CT procedure in patients treated for prostate cancer (PCa) who have biochemical recurrence (BR).</p></sec><sec><title>Materials and methods</title><p id="Par2">Consecutive patients with a diagnosis of PCa who underwent a dual-phase PSMA-PET scan between September 2022 and December 2023, were retrospectively included. We analyzed the number and maximum SUV (SUVmax) of lesions only in the pelvic region (prostate, locoregional lymph nodes and bone), based on PSMA-RADS version 2.0 and miTNM criteria. To assess the potential diagnostic benefit of additional delayed pelvic PET/CT imaging as part of the PSMA-PET procedure, the change in molecular TNM classification was evaluated after the procedure.</p></sec><sec><title>Results</title><p id="Par3">Additional delayed pelvic PET/CT imaging as part of the PSMA-PET procedure resulted in a change in molecular TNM classification in 22 out of 136 patients (16.2%). The highest percentage change was obtained in the miN classification (14/22 patients), followed by the miT classification (7/22) and lastly miM (1/22). Moreover, we found that patients in whom delayed pelvic imaging resulted in a change in molecular TNM classification were significantly older and had a higher PSA level than those in whom delayed imaging did not provide additional information.</p></sec><sec><title>Conclusions</title><p id="Par4">Pelvic delayed imaging in patients with biochemical recurrence of prostate cancer undergoing PET/CT with [<sup>18</sup>F]DCFPYL shows a non-negligible influence on patient staging, modifying the miTNM classification in 16.2% of cases, with pelvic lymphatic involvement benefiting the most from the dual study.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s41824-025-00238-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Prostate cancer</kwd><kwd>Dual-phase</kwd><kwd>PSMA-PET</kwd><kwd>[<sup>18</sup>F]DCFPYL</kwd><kwd>PSMA-RADS.</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Switzerland AG 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">In the last decade, positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA) has become the preferred diagnostic test of choice for restaging patients with biochemical recurrence (BR) of prostate cancer (PCa) ((Trabulsi et al. <xref ref-type="bibr" rid="CR1">2020</xref>). Among the many drugs developed in PET imaging, [<sup>18</sup>F]DCFPYL (2-(3-{1-carboxy-5-[(6&#x02013;18&#x000a0;F-fluoro-pyridin-3-carbonyl)-amino]-pentenyl}-ureido)-pentanodioic acid) has shown great utility in the evaluation of these patients (Morris et al. <xref ref-type="bibr" rid="CR2">2021</xref>; Song et al. <xref ref-type="bibr" rid="CR3">2020</xref>; Wondergem et al. <xref ref-type="bibr" rid="CR4">2017</xref>; Rowe et al. <xref ref-type="bibr" rid="CR5">2016</xref>). </p><p id="Par6">However, identification of recurrence in PCa patients is particularly limited by urinary excretion of the tracer, which may reduce accuracy when residual disease is in the prostate bed or periureteral lymph nodes ((Bauckneht et al. <xref ref-type="bibr" rid="CR6">2023</xref>). An alternative for future studies could be the use of [<sup>18</sup>F]F-PSMA-1007 which is excreted hepatically rather than renally and may have better diagnostic efficacy for detecting local recurrence in the bladder area ((Giesel et al. <xref ref-type="bibr" rid="CR7">2017</xref>).</p><p id="Par7">To date, few publications have assessed the diagnostic value of dual imaging in the [<sup>18</sup>F]DCFPYL PET/CT procedure with an acquisition at 60&#x000a0;min post-radiotracer administration and a delayed image obtained at 120&#x02013;180&#x000a0;min. Implementing a delayed image faces clinical challenges, such as patient compliance, scheduling and PET/CT workflows ((Bauckneht et al. <xref ref-type="bibr" rid="CR6">2023</xref>; Koehler et al. <xref ref-type="bibr" rid="CR8">2022</xref>; Morawitz et al. <xref ref-type="bibr" rid="CR9">2022</xref>).</p><p id="Par8">The latest EANM/SNMMI ((Fendler et al. <xref ref-type="bibr" rid="CR10">2023</xref>) guideline recommends imaging 60&#x000a0;min after radiopharmaceutical injection, leaving second-stage abdomino-pelvic imaging as an optional procedure.</p><p id="Par9">Therefore, the combined protocol with additional delayed imaging is not standardised in the clinical setting and its added clinical value still needs to be clarified ((Alberts et al. <xref ref-type="bibr" rid="CR11">2021</xref>).</p><p id="Par10">The aim of this study was to evaluate the added diagnostic value of additional second stage pelvic scanning as part of the [<sup>18</sup>F]DCFPYL PET/CT procedure after bladder emptying, in patients treated for PCa who have BR.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patients</title><p id="Par11">Consecutive patients with a diagnosis of PCa, who were being studied for suspected BR or for restaging in selected high-risk cases, who underwent a dual-phase PSMA-PET scan between September 2022 and December 2023, were retrospectively included.</p><p id="Par12">The study was conducted in accordance with the regulations of the Hospital Ethics Committee in line with the principles outlined in the Declaration of Helsinki.</p></sec><sec id="Sec4"><title>PSMA-PET procedure</title><p id="Par13">No fasting was required, and no diuretics were administered prior to imaging. Images were acquired using a Discovery MI 5R digital PET/CT machine (General Electric Healthcare, USA) following intravenous injection of a standard dose of 314.5 MBq of [<sup>18</sup>F]DCFPYL (Pylclari<sup>&#x000ae;</sup> CuriumPharmaSpain).</p><p id="Par14">Within 60&#x000a0;min after injection, a first image was acquired from the middle third of the femur to the vertex, with an acquisition time of 3&#x000a0;min/bed. An image acquisition of the pelvis was systematically performed within 120&#x000a0;min, with an acquisition time of 5&#x000a0;min/bed. A low-dose CT acquisition was used with the following settings: voltage 120 KV reference current 130 mAs and slice thickness 3.75&#x000a0;mm.</p><p id="Par15">PET images were reconstructed with a Bayesian penalised likelihood Q.Clear<sup>&#x000ae;</sup> (Discovery MI) reconstruction algorithm with a beta factor of 600 for both early-phase and delayed-phase images. CT attenuation correction was performed in all patients. Scans were analysed with Hermes Medical Solutions software.</p></sec><sec id="Sec5"><title>Image interpretation</title><p id="Par16">The images were evaluated independently by two experienced nuclear physicians. Discrepancies were resolved in a consensus reading. The readers were blinded to the clinical data of the patients.</p><p id="Par17">We included in the analysis the location of lesions in the pelvic region only, both in early and second-stage imaging, analysing number and maximum SUV (SUVmax) of lesions for each of the pelvic regions (prostate, locoregional lymph nodes and bone), based on PSMA-RADS version 2.0 and miTNM criteria ((Rowe et al. <xref ref-type="bibr" rid="CR12">2018</xref>; Eiber et al. <xref ref-type="bibr" rid="CR13">2018</xref>). </p><p id="Par18">To measure background SUVmax, a region of interest was placed in the left gluteus maximus muscle on early and delayed phase PET/CT.</p><p id="Par19">For each pelvic region the following values were calculated:</p><p id="Par20">
<list list-type="bullet"><list-item><p id="Par21">SUVratio early&#x02009;=&#x02009;SUVmax early / SUVmax gluteus.</p></list-item><list-item><p id="Par22">SUVratio delay&#x02009;=&#x02009;SUVmax delay/ SUVmax gluteal.</p></list-item><list-item><p id="Par23">&#x00394;SUVmax&#x02009;=&#x02009;SUVmax early &#x02013; SUVmax delay.</p></list-item><list-item><p id="Par24">SUVmax IR = (&#x00394;SUVmax / SUVmax early) x 100.</p></list-item><list-item><p id="Par25">SUVmax relation&#x02009;=&#x02009;SUVmax delay / SUVmax early.</p></list-item><list-item><p id="Par26">&#x00394;SUVratio&#x02009;=&#x02009;SUVratio early &#x02013;SUVratio delay.</p></list-item><list-item><p id="Par27">SUVratio IR = (&#x00394;SUVratio / SUVratio early) x 100.</p></list-item><list-item><p id="Par28">SUVratio relation&#x02009;=&#x02009;SUVratio delay / SUVratio early.</p></list-item></list>
</p><p id="Par29">In addition, [<sup>18</sup>F]DCFPYL uptake deposits were also qualitatively analysed, differentiating lesions into malignant or benign, using as reference standard histopathology when available, or follow-up imaging with PSMA-PET, bone scan, CT, MRI and/or PSA decline at 6 months after treatment. Furthermore, a decrease in PSA value during follow-up in those patients in whom active surveillance was chosen was also considered as a reference standard.</p><p id="Par30">Malignant lesions were considered to be PCa-related if one of the following criteria was met: histopathology of the lesion showed adenocarcinoma of the prostate, follow-up imaging showed an increase in size or number of lesions or a decrease in size or number of lesions after treatment (MRI, CT, Bone scan or [<sup>18</sup>F]Pylclari PET/CT), and when there was an increase in PSA during follow-up or a decrease in PSA in response to treatment. If the above conditions were not met, they were determined to be benign lesions.</p><p id="Par31">To assess the potential diagnostic benefit of additional delayed pelvic PET/CT imaging as part of the PSMA-PET procedure, the change in molecular TNM classification was evaluated after the procedure.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par32">Categorical variables were expressed as frequency and percentage and analysed using the &#x003c7;2 test or Fisher&#x02019;s exact test. Continuous variables were expressed as mean and standard deviation (SD) or median and interquartile range (IQR).</p><p id="Par33">For quantitative variables, normal distribution was assessed with the Saphiro-Wilk test. Student&#x02019;s t-test and its non-parametric alternative, the Mann-Whitney U-test, were used to study mean differences between groups. For the different statistical tests, 95% confidence intervals were calculated for quantitative variables, and Odds Ratio [95% CI] for qualitative variables. Significant differences were determined to exist when <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p><p id="Par34">Statistical analysis was calculated using IBM SPSS<sup>&#x000ae;</sup> Statistics version 24.</p></sec></sec><sec id="Sec7"><title>Results</title><p id="Par35">A total of 136 patients undergoing dual-phase PSMA-PET with [<sup>18</sup>F]DCFPYL were included, of which 124 (91.2%) were being studied in the context of biochemical recurrence, while in 12 patients (8.8%) the study was requested for initial restaging. The baseline characteristics of the patients are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par36">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2">Patient characteristics (<italic>n</italic>&#x02009;=&#x02009;136)</th></tr></thead><tbody><tr><td align="left">
<bold>Age (years)*</bold>
</td><td align="left"><p>66.5 (6.7)</p><p>(49&#x02013;84)</p></td></tr><tr><td align="left"><bold>Gleason (n</bold>,<bold> %) [1]</bold></td><td align="left"/></tr><tr><td align="left">
<bold>4</bold>
</td><td align="left">1 (0.7%)</td></tr><tr><td align="left">
<bold>5</bold>
</td><td align="left">2 (1.5%)</td></tr><tr><td align="left">
<bold>6</bold>
</td><td align="left">30 (22.2%)</td></tr><tr><td align="left">
<bold>7</bold>
</td><td align="left">66 (48.9%)</td></tr><tr><td align="left">
<bold>8</bold>
</td><td align="left">24 (17.8%)</td></tr><tr><td align="left">
<bold>9</bold>
</td><td align="left">11 (8.1%)</td></tr><tr><td align="left">
<bold>10</bold>
</td><td align="left">1 (0.7%)</td></tr><tr><td align="left">
<bold>PSA at the time of PSMA-PET (ng/ml)**</bold>
</td><td align="left"><p>0.45 (0.7)</p><p>(0.01- 4,3)</p></td></tr><tr><td align="left"><bold>Clinical justification PSMA-PET (n</bold>,<bold> %)</bold></td><td align="left"/></tr><tr><td align="left">
<bold>Initial staging</bold>
</td><td align="left">12 (8.8%)</td></tr><tr><td align="left">
<bold>Biochemical recurrence</bold>
</td><td align="left">124 (91.2%)</td></tr><tr><td align="left"><bold>Reference standard (n</bold>,<bold> %)</bold></td><td align="left">52 (38.2%)</td></tr><tr><td align="left">
<bold>Histopathology</bold>
</td><td align="left">1</td></tr><tr><td align="left">
<bold>Follow-up images</bold>
</td><td align="left"/></tr><tr><td align="left">MRI</td><td align="left">1</td></tr><tr><td align="left">CT</td><td align="left">14</td></tr><tr><td align="left">Bone scan</td><td align="left">7</td></tr><tr><td align="left">PSMA-PET</td><td align="left">18</td></tr><tr><td align="left">
<bold>PSA after treatment</bold>
</td><td align="left">32</td></tr><tr><td align="left">
<bold>Follow-up PSA</bold>
</td><td align="left">7</td></tr></tbody></table><table-wrap-foot><p>
<italic>*Quantitative variables expressed by mean (SD) and range (minimum - maximum). ** Quantitative variables expressed as median (IQR) and range (minimum - maximum). [Missing values]</italic>
</p></table-wrap-foot></table-wrap>
</p><p id="Par37">The mean age was 66.5 years (SD 6.7; range: 49&#x02013;84 years). Most patients had a Gleason score equal to or greater than 7 (<italic>n</italic>&#x02009;=&#x02009;102/136; 75%), with Gleason 7 being the predominant score (<italic>n</italic>&#x02009;=&#x02009;66/136; 48.9%).</p><p id="Par38">Prostate lesions were detected in a total of 16/136 patients (11.8%), pelvic lymph nodes in 26/136 patients (19.1%) and pelvic bone lesions in 3/136 patients (2.2%).</p><p id="Par39">In early-phase PET/CT, the SUVmax for local recurrences, pelvic lymph node metastases and pelvic bone metastases was 12.75&#x02009;&#x000b1;&#x02009;11.7, 26.35&#x02009;&#x000b1;&#x02009;42.6 and 4.54&#x02009;&#x000b1;&#x02009;114.9, respectively, while delayed-phase SUVmax was 17.9&#x02009;&#x000b1;&#x02009;15.6, 32.9&#x02009;&#x000b1;&#x02009;47.7 and 5.35&#x02009;&#x000b1;&#x02009;127.9 respectively, there being no statistically significant difference between them (<italic>p</italic>&#x02009;=&#x02009;0.221). There were also no differences in SUVmax on delayed-phase PET/CT between prostate lesions and pelvic lymph nodes, as well as in &#x00394;SUVmax, IR and ratio values (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par40">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Distribution of SUVmax and SUV ratio values and the different SUV coefficients in malignant lesions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="6">SUV maximum</th></tr><tr><th align="left">SUVmax early</th><th align="left">SUVmax delay</th><th align="left">&#x00394;SUVmax<break/>[CI 95%]</th><th align="left">SUVmax IR</th><th align="left">SUVmax relation</th><th align="left">Differences&#x02020;</th></tr></thead><tbody><tr><td align="left"><p>
<bold>Prostate lesions</bold>
</p><p>(<bold><italic>n</italic></bold>&#x02009;=&#x02009;<bold>16</bold>)</p></td><td align="left"><p>12.75 (11.7)</p><p>(3.85&#x02013;52.9)</p></td><td align="left"><p>17.9 (15.6)</p><p>(7-70.4)</p></td><td align="left"><p>1.5 (0.4)</p><p>(0.98&#x02013;2.2)</p><p>[CI -7.85; -2.44]</p></td><td align="left"><p>-5,15 (5,1)</p><p>(-17,45&#x02009;&#x02212;&#x02009;0,25)</p></td><td align="left"><p>-50.77 (39.58)</p><p>(-120.11&#x02013;1.89)</p></td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.001</td></tr><tr><td align="left"><p>
<bold>Pelvic lymph nodes</bold>
</p><p>(<bold><italic>n</italic></bold>&#x02009;=&#x02009;<bold>26</bold>)</p></td><td align="left"><p>26.35 (42.6)</p><p>(1.3&#x02013;169)</p></td><td align="left"><p>32.9 (47.7)</p><p>(1.84&#x02013;183)</p></td><td align="left"><p>-6.6 (7.2)</p><p>(-29.1-0.99)</p><p>[CI -9.51; -3.67]</p></td><td align="left"><p>-57,5 (68,4)</p><p>(-280-26,83)</p></td><td align="left"><p>1.57 (0.68)</p><p>(0.73&#x02013;3.8)</p></td><td align="left"><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">
<bold>Differences</bold>
</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.221</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.231</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.489</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.724</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.724</td><td align="left"/></tr><tr><td align="left"/><td align="left" colspan="6">
<bold>SUV ratio</bold>
</td></tr><tr><td align="left"/><td align="left">
<bold>SUVratio early</bold>
</td><td align="left">
<bold>SUVratio delay</bold>
</td><td align="left"><p>
<bold>&#x00394;SUVratio</bold>
</p><p>
<bold>[CI 95%]</bold>
</p></td><td align="left">
<bold>SUVratio IR</bold>
</td><td align="left">
<bold>SUVratio relation</bold>
</td><td align="left"><bold>Diferencias</bold>&#x02020;</td></tr><tr><td align="left"><p>
<bold>Prostate lesions</bold>
</p><p>(<bold><italic>n</italic></bold>&#x02009;=&#x02009;<bold>16</bold>)</p></td><td align="left"><p>12.3 (8.5)</p><p>(3.28&#x02013;37.8)</p></td><td align="left"><p>21.9 (15.46)</p><p>(5.8&#x02013;70.4)</p></td><td align="left"><p>-8.89 (8)</p><p>(-32.56 &#x02013; (-1.54))</p><p>[CI -13.1; -4.7]</p></td><td align="left"><p>-81.97 (56.27)</p><p>(-224.9 &#x02013; (-14.61))</p></td><td align="left"><p>1,81 (0.56)</p><p>(1.15&#x02013;3.25)</p></td><td align="left"><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><p>
<bold>Pelvic lymph nodes</bold>
</p><p>(<bold><italic>n</italic></bold>&#x02009;=&#x02009;<bold>26</bold>)</p></td><td align="left"><p>61.3 (46.3)</p><p>(1.4-178.4)</p></td><td align="left"><p>37 (50.6)</p><p>(1-179.4)</p></td><td align="left"><p>24.3 (68.5)</p><p>(-113-177)</p><p>[CI -3.34;51.96]</p></td><td align="left"><p>-94.25 (591)</p><p>(-2955-99.44)</p></td><td align="left"><p>1.9 (5.9)</p><p>(0.01&#x02013;30.56)</p></td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.082</td></tr><tr><td align="left">
<bold>Differences</bold>
</td><td align="left"><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.234</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.062</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.935</td><td align="left"><italic>p</italic>&#x02009;=&#x02009;0.935</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>
<italic>Quantitative variables expressed as mean (SD) and range (minimum - maximum)</italic>
</p><p>&#x02020; <italic>Student&#x02019;s t-test for two independent samples</italic></p></table-wrap-foot></table-wrap>
</p><p id="Par41">However, early-phase SUV ratio were significantly higher in pelvic lymph node metastases compared to prostate lesions (61.3 vs. 12.3; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), with no difference found between the two groups in delayed-phase SUV ratio.</p><p id="Par42">SUVmax was significantly higher on delayed-phase PET/CT compared to early-phase PET/CT in both prostate lesions (SUVmax delay 17.9 vs. SUVmax early 12.75; <italic>p</italic>&#x02009;=&#x02009;0.001) and pelvic lymph nodes (SUVmax delay 32.9 vs. SUVmax early 26.35; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p><p id="Par43">Likewise, significantly higher SUV ratio was observed in the delayed phase compared to the early phase in prostate lesions (SUV ratio delay 21.9 vs. SUV ratio early 12.3, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), with no statistically significant differences found in pelvic lymph nodes.</p><p id="Par44">The reference standard was assessed in 52 patients (histopathology&#x02009;=&#x02009;1; MRI&#x02009;=&#x02009;1; CT&#x02009;=&#x02009;14; bone scan&#x02009;=&#x02009;7; PSMA-PET&#x02009;=&#x02009;18; PSA after treatment&#x02009;=&#x02009;32; follow-up PSA&#x02009;=&#x02009;7), classifying the initial suspicious lesion as malignant in 75% of patients (<italic>n</italic>&#x02009;=&#x02009;39) and as benign in 25% (<italic>n</italic>&#x02009;=&#x02009;13).</p><p id="Par45">For malignant lesions, higher delayed-phase SUVmax, delayed-phase SUV ratio, &#x00394;SUVmax and IR were observed, without these differences being statistically significant (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05). The SUVmax and the different SUV ratios according to the lesion classified as benign and malignant are detailed in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.</p><p id="Par46">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Maximum SUV values (SUVmax) and SUV coefficients as a function of the lesion classified as benign and malignant according to the reference standard</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="4">Benign lesions (n&#x02009;=&#x02009;13)</th><th align="left" colspan="4">Malignant lesions (n&#x02009;=&#x02009;39)</th><th align="left" rowspan="2">Asymptotic sig. (bilateral)</th></tr><tr><th align="left"/><th align="left">median</th><th align="left">IQR</th><th align="left">max</th><th align="left">min</th><th align="left">median</th><th align="left">IQR</th><th align="left">max</th><th align="left">min</th></tr></thead><tbody><tr><td align="left">SUVmax early</td><td char="." align="char">9,54</td><td char="." align="char">21,3</td><td char="." align="char">63,8</td><td align="left">1,8</td><td char="." align="char">8,8</td><td char="." align="char">11,8</td><td char="." align="char">169</td><td align="left">1,33</td><td char="." align="char">0,96</td></tr><tr><td align="left">SUVmax delay</td><td char="." align="char">7,3</td><td char="." align="char">15,9</td><td char="." align="char">66,5</td><td align="left">1,9</td><td char="." align="char">9,2</td><td char="." align="char">13,9</td><td char="." align="char">143,2</td><td align="left">1,6</td><td char="." align="char">0,739</td></tr><tr><td align="left">SUV ratio early</td><td char="." align="char">11,36</td><td char="." align="char">36,2</td><td char="." align="char">123,1</td><td align="left">1,6</td><td char="." align="char">11,96</td><td char="." align="char">14,7</td><td char="." align="char">183</td><td align="left">1,8</td><td char="." align="char">0,46</td></tr><tr><td align="left">SUV ratio delay</td><td char="." align="char">11,1</td><td char="." align="char">32,6</td><td char="." align="char">121,9</td><td align="left">2,9</td><td char="." align="char">17</td><td char="." align="char">23</td><td char="." align="char">179,4</td><td align="left">1</td><td char="." align="char">0,337</td></tr><tr><td align="left">&#x025b3;SUVmax</td><td char="." align="char">3</td><td char="." align="char">15,03</td><td char="." align="char">77,7</td><td align="left">-7,7</td><td char="." align="char">3,7</td><td char="." align="char">3,7</td><td char="." align="char">29,1</td><td align="left">-0,4</td><td char="." align="char">0,492</td></tr><tr><td align="left">IR (%)</td><td char="." align="char">30,6</td><td char="." align="char">84,9</td><td char="." align="char">171</td><td align="left">-331,9</td><td char="." align="char">31,83</td><td char="." align="char">31,83</td><td char="." align="char">912,3</td><td align="left">-2,97</td><td char="." align="char">0,209</td></tr><tr><td align="left">SUVratio early/delay</td><td char="." align="char">1,31</td><td char="." align="char">0,83</td><td char="." align="char">2,71</td><td align="left">-0,33</td><td char="." align="char">1,3</td><td char="." align="char">1,3</td><td char="." align="char">3,8</td><td align="left">0,97</td><td char="." align="char">0,369</td></tr></tbody></table><table-wrap-foot><p>
<italic>IQR&#x02009;=&#x02009;Interquartile range</italic>
</p></table-wrap-foot></table-wrap>
</p><p id="Par47">Additional delayed pelvic PET/CT imaging as part of the PSMA-PET procedure resulted in a change in molecular TNM staging in 22 out of 136 patients (16.2%). The highest percentage change was obtained in the miN classification (14/22 patients, 63.6%), followed by the miT classification (7/22; 31.8%) and lastly miM (1/22 patients; 4.5%).</p><p id="Par48">As for the patients in whom miN was modified (14/22), in most cases (8/14), the late miN was re-staged from miN0 to miN1: in 6/8 due to increased uptake in doubtful nodes, as can be seen in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, and in 2/8 due to an increase in the number of pelvic lymph nodes. In 3/14 patients new lymph nodes appeared in the delayed image that changed the miN1 to N2. In 3/14 patients the degree of uptake of the lymph nodes visualised in the early image decreased, which meant a change from miN1 to miN0.</p><p id="Par49">
<fig id="Fig1"><label>Fig. 1</label><caption><p><bold>A</bold> and <bold>B</bold>) Axial views and MIP of the early phase PET-PSMA showing a small right pararectal lymph node with mild PSMA expression of uncertain etiology. <bold>C</bold> and <bold>D</bold>) Second-stage axial and MIP images showing a moderate increase in PSMA expression in this lymph node and suggesting malignancy. In this patient, the PSA level decreased after RT administration in the referred lymphatic regions</p></caption><graphic xlink:href="41824_2025_238_Fig1_HTML" id="d33e1152"/></fig>
</p><p id="Par50">In those patients in whom the miT was modified (7/22 patients), in 5/7 the local recurrence was appropriately categorised due to delayed imaging from miT0 to miTr. In most cases (4/5) a doubtful deposit was evident on early imaging, but could be confirmed by the second stage scan, while in the other case the focus was new onset. In 2/7 patients the suspicious focus in the prostate on early imaging disappeared on delayed imaging, downstaging from miTr to T0.</p><p id="Par51">The only patient in whom the delayed image led to a change in the staging of bone involvement, the degree of uptake of a pelvic lesion decreased, as can be seen in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, and was then downgraded from miM1b to miM0, bearing in mind, moreover, that there were no other hyperintense bone lesions in the rest of the skeleton.</p><p id="Par52">
<fig id="Fig2"><label>Fig. 2</label><caption><p><bold>(A)</bold> Axial section of PET-PSMA in early phase showing a focal increase in PSMA expression in the left ilium bone (SUVmax 3.7), with no underlying morphological lesion and of doubtful pathological value. <bold>(B)</bold> Same axial section in second-stage showing decreased PSMA expression (SUVmax 2.4), therefore indicating a nonspecific finding</p></caption><graphic xlink:href="41824_2025_238_Fig2_HTML" id="d33e1175"/></fig>
</p><p id="Par53">Finally, we found that patients in whom delayed pelvic imaging resulted in a change in molecular TNM classification were significantly older (70.32&#x02009;&#x000b1;&#x02009;7.3 vs. 65.7&#x02009;&#x000b1;&#x02009;6.32 years; <italic>p</italic>&#x02009;=&#x02009;0.006) and had a higher PSA level (1.14&#x02009;&#x000b1;&#x02009;1.2 ng/ml vs. 0.69&#x02009;&#x000b1;&#x02009;0.75 ng/ml; <italic>p</italic>&#x02009;=&#x02009;0.024) than those in whom delayed imaging did not provide additional information (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).</p><p id="Par54">
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Differences in baseline patient characteristics according to whether delayed pelvic PET/CT imaging had diagnostic benefit in terms of change in miTNM staging (no change/change in miTNM classification)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">No change (<italic>n</italic>&#x02009;=&#x02009;113)</th><th align="left">Yes change (<italic>n</italic>&#x02009;=&#x02009;22)</th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">
<bold>Age (years)*</bold>
</td><td align="left">65.7 (6.32) (49&#x02013;78)</td><td align="left">70.32 (7.3) (56&#x02013;84)</td><td char="." align="char">0.006 &#x02020;</td></tr><tr><td align="left">
<bold>PSA (ng/ml)**</bold>
</td><td align="left">0.69 (0.75) (0.01&#x02013;3.7)</td><td align="left">1.14 (1.2) (0.25&#x02013;4.29)</td><td char="." align="char">0.024 &#x000a5;</td></tr><tr><td align="left"><bold>Gleason (%</bold>,<bold> n)</bold></td><td align="left"/><td align="left"/><td align="left" rowspan="8">0.816 <bold>&#x02021;</bold></td></tr><tr><td align="left">
<bold>4</bold>
</td><td align="left">0% (0)</td><td align="left">4.5% (1)</td></tr><tr><td align="left">
<bold>5</bold>
</td><td align="left">1.8% (2)</td><td align="left">0% (0)</td></tr><tr><td align="left">
<bold>6</bold>
</td><td align="left">23% (26)</td><td align="left">18.2% (4)</td></tr><tr><td align="left">
<bold>7</bold>
</td><td align="left">48.7% (55)</td><td align="left">50% (11)</td></tr><tr><td align="left">
<bold>8</bold>
</td><td align="left">17.7% (20)</td><td align="left">18.2% (4)</td></tr><tr><td align="left">
<bold>9</bold>
</td><td align="left">8% (9)</td><td align="left">9.1% (2)</td></tr><tr><td align="left">
<bold>10</bold>
</td><td align="left">0.9% (1)</td><td align="left">0% (0)</td></tr></tbody></table><table-wrap-foot><p>
<italic>*Quantitative variables expressed by mean (SD) and range (minimum - maximum). ** Quantitative variables expressed as median (IQR) and range (minimum - maximum)</italic>
</p><p>
<italic>&#x02020;Student&#x02019;s t-test for two independent samples</italic>
</p><p>
<italic>&#x000a5; U-Mann Whitney test</italic>
</p><p>
<italic>&#x02021; Chi-square test for linear trend</italic>
</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec8"><title>Discussion</title><p id="Par55">In this study we retrospectively analysed 136 patients who underwent dual-phase PSMA-PET with [<sup>18</sup>F]DCFPYL. Most of the patients (91.2%) were referred to our unit for biochemical recurrence with PSA value between 0.2 and 2 ng/ml (approved indication). Therefore, in these patients, the tumour burden to be expected is low, with a small number of lesions, which may also be small in size and/or with a low degree of uptake of PSMA, which could generate diagnostic doubts. For this reason, dual imaging may help to clarify these doubtful lesions. This is due to the continued accumulation of PSMA in prostate cancer lesions, leading to increased detectability of small lesions ((Schmuck et al. <xref ref-type="bibr" rid="CR14">2017a</xref>, <xref ref-type="bibr" rid="CR17">b</xref>). </p><p id="Par56">In our group of patients there was a high percentage of negative studies (46.3%). In the remaining 73 patients 141 lesions were found, with a change in the miTNM after delayed imaging in 22 patients, i.e. 16.2% of the total.</p><p id="Par57">In 7 of the 22 patients in whom the miT was changed, in one case a lesion was detected on delayed imaging that was not visible on early imaging. This patient showed a decrease in PSA following radiotherapy after the PET study. In two other cases, the early imaging findings were defined as non-malignant lesions due to the decreased SUVmax on delayed imaging. In one of these cases, a subsequent PSMA-PET was negative, confirming the non-malignant nature of the finding. Finally, in the remaining four cases, doubtful images were evident on early imaging due to low uptake, which were considered malignant lesions due to the increased SUVmax. Of these 4 patients, 3 patients received RT and there was a decrease in PSA in 2 of them and in one patient who did not receive treatment, PSA was increased in subsequent controls.</p><p id="Par58">Regarding miN, there were 14 patients in whom delayed imaging had an impact on patient classification. Three patients showed a lymph node with low PSMA uptake on early imaging and decreased SUVmax on delayed imaging and were therefore classified as non-malignant. Subsequent follow-up showed a decrease in PSA without any treatment. However, in 6 other cases, the increase in SUVmax between early and delayed imaging allowed the detected lymph nodes to be classified as malignant. After treatment, a decrease in PSA was observed in these patients. In addition, five other patients had hyperenhancing lymph nodes detected on delayed imaging that had not been identified on early imaging, with three patients going from miN0 to miN1 and two patients from miN1 to miN2.</p><p id="Par59">Finally, in miM, in one patient with a doubtful image due to its low degree of uptake, SUVmax decreased in the delayed imaging, and was therefore considered non-malignant.</p><p id="Par60">As in other studies, in our sample of patients we also found more lesions in the delayed imaging than in the early imaging, being mainly in the pelvic lymphatic involvement where the delayed imaging contributed most, corresponding to 63.6% of the changes found ((Alberts et al. <xref ref-type="bibr" rid="CR11">2021</xref>; Afshar-Oromieh et al. <xref ref-type="bibr" rid="CR15">2017</xref>).</p><p id="Par61">In 16.2% of patients, there was a change in the miTNM between early imaging and delayed imaging. This value is above other authors, such as Wondergem et al. ((Wondergem et al. <xref ref-type="bibr" rid="CR4">2017</xref>), who found a 9.2% change in TNM. However, it is much lower than those found in other studies such as that of ((Librizzi et al. <xref ref-type="bibr" rid="CR16">2023</xref>), who found a change in TNM of 66.7%, although the greatest number of changes also occurred in lymphatic involvement (55.6% vs. 63.6%).</p><p id="Par62">The value of delayed imaging has been extensively studied in PET studies of oncological patients, fundamentally in FDG studies, demonstrating an increase in sensitivity and specificity due to the fact that the progressive increase in uptake by malignant lesions and the decrease in radiotracer in the rest of the tissues leads to an increase in the lesion/background ratio. The results of these studies support the inclusion of delayed imaging, as it not only detects lesions not evident in the baseline image, but also allows the dynamics of uptake by the lesion detected in the initial image to be assessed. Several authors have analysed the value of delayed imaging in patients with biochemical recurrence of prostate cancer using different radiotracers ([<sup>68</sup>Ga]PSMA, [<sup>18</sup>F]PSMA, [<sup>18</sup>F]DCFPYL). International guidelines recommend acquisition of an image around 60&#x000a0;min post-injection, but delayed imaging is under discussion, as well as the best time for acquisition (90&#x000a0;min p.i., 120&#x000a0;min p.i. and even 180&#x000a0;min p.i.). Schmuck et al.<sup>17</sup> found that only 3.4% of lesions suggestive of disease recurrence were detected at 3&#x000a0;h post-injection.</p><p id="Par63">In our study, a baseline image was systematically performed at 60&#x000a0;min and a delayed imaging at 120&#x000a0;min post-injection. Given that, in most cases, the second-stage imaging clarified the etiology of a doubtful uptake deposit pre-existing in the early imaging, and the increased radiation dose involved in delayed imaging CT and equipment workloads, delayed imaging should probably be reserved for selected cases. In our study, the patients who benefited from delayed imaging were those who were older and had a higher PSA level, without finding a statistical relationship with the Gleason score.</p><p id="Par64">Thus, further prospective studies should be carried out with a larger number of patients to confirm these results and, if confirmed, reserve dual imaging for this group of patients, which would avoid unnecessarily prolonged stays in PET units for a large number of patients and would lighten the workload of the teams.</p><p id="Par65">Our study includes a number of limitations that need to be mentioned. Firstly, it is a single-centre, retrospective study. Secondly, a reference standard was only available in 38.2% of the patients, and we were unable to use the same gold standard in all cases, which could significantly affect the reproducibility of the results. In addition, most of the suspicious lesions did not have histopathological confirmation, although clinical-radiological follow-up is a well-established reference standard. Thirdly, most of the patients analysed were patients with biochemical recurrence, so the role of this dual imaging in the initial staging of patients diagnosed with prostate cancer cannot be assessed.</p></sec><sec id="Sec9"><title>Conclusions</title><p id="Par66">In conclusion, pelvic delayed imaging in patients with biochemical recurrence of prostate cancer undergoing PET/CT with [<sup>18</sup>F]DCFPYL shows a non-negligible influence on patient staging, modifying the miTNM classification in 16.2% of cases, with pelvic lymphatic involvement benefiting the most from the dual study.</p><p id="Par67">Older patients with higher PSA are the group of patients in whom late acquisition provides the most additional information.</p></sec><sec id="Sec10" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41824_2025_238_MOESM1_ESM.odt"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41824_2025_238_MOESM2_ESM.docx"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Ana Rodr&#x000ed;guez-Pajuelo and Miriam Guerra-G&#x000f3;mez are considered the first authors of this manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The urology department has supported in collecting patients.</p></ack><notes notes-type="funding-information"><title>Funding</title><p>The authors state that this work has not received any funding.</p></notes><notes><title>Declarations</title><notes id="FPar3"><title>Ethical approval</title><p id="Par74">Institutional Review Board approval was obtained.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par70">The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.</p></notes><notes id="FPar2"><title>Guarantor</title><p id="Par75">The scientific guarantor of this publication is Rosa Mar&#x000ed;a &#x000c1;lvarez P&#x000e9;rez.</p></notes><notes id="FPar4"><title>Statistics and biometry</title><p id="Par76">Miriam Guerra G&#x000f3;mez has significant statistical expertise.</p></notes><notes id="FPar5"><title>Informed consent</title><p id="Par73">Informed consent was obtained from all patients in this study.</p></notes><notes id="FPar6"><title>Study subjects or cohorts overlap</title><p id="Par173">No subject subjects or cohort overlap reported.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Afshar-Oromieh</surname><given-names>A</given-names></name><name><surname>Sattler</surname><given-names>LP</given-names></name><name><surname>Mier</surname><given-names>W</given-names></name><name><surname>Hadaschik</surname><given-names>BA</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><name><surname>Holland-Letz</surname><given-names>T</given-names></name><etal/></person-group><article-title>The clinical impact of additional late PET/CT imaging with</article-title><source>J Nucl Med</source><year>2017</year><volume>58</volume><issue>5</issue><fpage>750</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.2967/jnumed.116.183483</pub-id><pub-id pub-id-type="pmid">28062595</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Afshar-Oromieh A, Sattler LP, Mier W, Hadaschik BA, Debus J, Holland-Letz T et al (2017) The clinical impact of additional late PET/CT imaging with. J Nucl Med 58(5):750&#x02013;755<pub-id pub-id-type="pmid">28062595</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Alberts</surname><given-names>I</given-names></name><name><surname>Niklas-H&#x000fc;nermund</surname><given-names>J</given-names></name><name><surname>Sachpekidis</surname><given-names>C</given-names></name><name><surname>Zacho</surname><given-names>HD</given-names></name><name><surname>Mingels</surname><given-names>C</given-names></name><name><surname>Dijkstra</surname><given-names>L</given-names></name><name><surname>Bohn</surname><given-names>KP</given-names></name><name><surname>L&#x000e4;ppchen</surname><given-names>T</given-names></name><name><surname>Gourni</surname><given-names>E</given-names></name><name><surname>Rominger</surname><given-names>A</given-names></name><name><surname>Afshar-Oromieh</surname><given-names>A</given-names></name></person-group><article-title>Combination of forced diuresis with additional late imaging in</article-title><source>Eff Lesion Visibility Radiotracer Uptake J NuclMed</source><year>2021</year><volume>62</volume><issue>9</issue><fpage>1252</fpage><lpage>1257</lpage></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Alberts I, Niklas-H&#x000fc;nermund J, Sachpekidis C, Zacho HD, Mingels C, Dijkstra L, Bohn KP, L&#x000e4;ppchen T, Gourni E, Rominger A, Afshar-Oromieh A (2021) Combination of forced diuresis with additional late imaging in. Eff Lesion Visibility Radiotracer Uptake J NuclMed 62(9):1252&#x02013;1257</mixed-citation></citation-alternatives></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Bauckneht</surname><given-names>M</given-names></name><name><surname>Miceli</surname><given-names>A</given-names></name><name><surname>Signori</surname><given-names>A</given-names></name><name><surname>Albano</surname><given-names>D</given-names></name><name><surname>Capitanio</surname><given-names>S</given-names></name><name><surname>Piva</surname><given-names>R</given-names></name><name><surname>Laudicella</surname><given-names>R</given-names></name><name><surname>Franchini</surname><given-names>A</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>F</given-names></name><name><surname>Riondato</surname><given-names>M</given-names></name><name><surname>Chiola</surname><given-names>S</given-names></name><name><surname>Marini</surname><given-names>C</given-names></name><name><surname>Fornarini</surname><given-names>G</given-names></name><name><surname>Scarale</surname><given-names>A</given-names></name><name><surname>Muni</surname><given-names>A</given-names></name><name><surname>Bertagna</surname><given-names>F</given-names></name><name><surname>Burger</surname><given-names>IA</given-names></name><name><surname>Sambuceti</surname><given-names>G</given-names></name><name><surname>Morbelli</surname><given-names>S</given-names></name></person-group><article-title>Combinedforced diuresis and late acquisitionon [</article-title><source>Clin practice-oriented Study EurRadiol</source><year>2023</year><volume>33</volume><issue>5</issue><fpage>3343</fpage><lpage>3353</lpage></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Bauckneht M, Miceli A, Signori A, Albano D, Capitanio S, Piva R, Laudicella R, Franchini A, D&#x02019;Amico F, Riondato M, Chiola S, Marini C, Fornarini G, Scarale A, Muni A, Bertagna F, Burger IA, Sambuceti G, Morbelli S (2023) Combinedforced diuresis and late acquisitionon [. Clin practice-oriented Study EurRadiol 33(5):3343&#x02013;3353</mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Eiber</surname><given-names>M</given-names></name><name><surname>Herrmann</surname><given-names>K</given-names></name><name><surname>Calais</surname><given-names>J</given-names></name><name><surname>Hadaschik</surname><given-names>B</given-names></name><name><surname>Giesel</surname><given-names>FL</given-names></name><name><surname>Hartenbach</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT</article-title><source>J NuclMed</source><year>2018</year><volume>59</volume><issue>3</issue><fpage>469</fpage><lpage>478</lpage></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M et al (2018) Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J NuclMed 59(3):469&#x02013;478</mixed-citation></citation-alternatives></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Fendler</surname><given-names>WP</given-names></name><name><surname>Eiber</surname><given-names>M</given-names></name><name><surname>Beheshti</surname><given-names>M</given-names></name><name><surname>Bomanji</surname><given-names>J</given-names></name><name><surname>Calais</surname><given-names>J</given-names></name><name><surname>Ceci</surname><given-names>F</given-names></name><name><surname>Cho</surname><given-names>SY</given-names></name><name><surname>Fanti</surname><given-names>S</given-names></name><name><surname>Giesel</surname><given-names>FL</given-names></name><name><surname>Goffin</surname><given-names>K</given-names></name><name><surname>Haberkorn</surname><given-names>U</given-names></name><name><surname>Jacene</surname><given-names>H</given-names></name><name><surname>Koo</surname><given-names>PJ</given-names></name><name><surname>Kopka</surname><given-names>K</given-names></name><name><surname>Krause</surname><given-names>BJ</given-names></name><name><surname>Lindenberg</surname><given-names>L</given-names></name><name><surname>Marcus</surname><given-names>C</given-names></name><name><surname>Mottaghy</surname><given-names>FM</given-names></name><name><surname>Oprea-Lager</surname><given-names>DE</given-names></name><name><surname>Osborne</surname><given-names>JR</given-names></name><name><surname>Piert</surname><given-names>M</given-names></name><name><surname>Rowe</surname><given-names>SP</given-names></name><name><surname>Sch&#x000f6;der</surname><given-names>H</given-names></name><name><surname>Wan</surname><given-names>S</given-names></name><name><surname>Wester</surname><given-names>HJ</given-names></name><name><surname>Hope</surname><given-names>TA</given-names></name><name><surname>Herrmann</surname><given-names>K</given-names></name></person-group><article-title>PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0</article-title><source>Eur J NuclMed Mol Imaging</source><year>2023</year><volume>50</volume><issue>5</issue><fpage>1466</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1007/s00259-022-06089-w</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Sch&#x000f6;der H, Wan S, Wester HJ, Hope TA, Herrmann K (2023) PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J NuclMed Mol Imaging 50(5):1466&#x02013;1486</mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Giesel</surname><given-names>FL</given-names></name><name><surname>Hadaschik</surname><given-names>B</given-names></name><name><surname>Cardinale</surname><given-names>J</given-names></name><name><surname>Radtke</surname><given-names>J</given-names></name><name><surname>Vinsensia</surname><given-names>M</given-names></name><name><surname>Lehnert</surname><given-names>W</given-names></name><etal/></person-group><article-title>F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2017</year><volume>44</volume><fpage>678</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1007/s00259-016-3573-4</pub-id><pub-id pub-id-type="pmid">27889802</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W et al (2017) F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 44:678&#x02013;688<pub-id pub-id-type="pmid">27889802</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Koehler</surname><given-names>D</given-names></name><name><surname>Sauer</surname><given-names>M</given-names></name><name><surname>Karimzadeh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Evaluation of [</article-title><source>EJNMMI Res</source><year>2022</year><volume>12</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.1186/s13550-022-00938-3</pub-id><pub-id pub-id-type="pmid">36210356</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Koehler D, Sauer M, Karimzadeh A et al (2022) Evaluation of [. EJNMMI Res 12:66<pub-id pub-id-type="pmid">36210356</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Librizzi</surname><given-names>D</given-names></name><name><surname>Eilsberger</surname><given-names>F</given-names></name><name><surname>Ottenthaler</surname><given-names>S</given-names></name><name><surname>Ebrahimifard</surname><given-names>A</given-names></name><name><surname>Luster</surname><given-names>M</given-names></name><name><surname>Yousefi</surname><given-names>BH</given-names></name></person-group><article-title>Diagnostic impact of dual-time PET/CT with</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><issue>4</issue><fpage>1052</fpage><pub-id pub-id-type="doi">10.3390/biomedicines11041052</pub-id><pub-id pub-id-type="pmid">37189670</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Librizzi D, Eilsberger F, Ottenthaler S, Ebrahimifard A, Luster M, Yousefi BH (2023) Diagnostic impact of dual-time PET/CT with. Biomedicines 11(4):1052<pub-id pub-id-type="pmid">37189670</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Morawitz</surname><given-names>J</given-names></name><name><surname>Kirchner</surname><given-names>J</given-names></name><name><surname>Hertelendy</surname><given-names>J</given-names></name><etal/></person-group><article-title>Is there a diagnostic benefit of late-phase abdomino-pelvic PET/CT after urination as part of whole-body</article-title><source>68Ga-PSMA-11 PET/CT Restaging Patients Biochem Recurrence Prostate cancer after Radical Prostatectomy? EJNMMI Res</source><year>2022</year><volume>12</volume><fpage>12</fpage></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Morawitz J, Kirchner J, Hertelendy J et al (2022) Is there a diagnostic benefit of late-phase abdomino-pelvic PET/CT after urination as part of whole-body. 68Ga-PSMA-11 PET/CT Restaging Patients Biochem Recurrence Prostate cancer after Radical Prostatectomy? EJNMMI Res 12:12</mixed-citation></citation-alternatives></ref><ref id="CR2"><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>MJ</given-names></name><name><surname>Rowe</surname><given-names>SP</given-names></name><name><surname>Gorin</surname><given-names>MA</given-names></name><name><surname>Saperstein</surname><given-names>L</given-names></name><name><surname>Pouliot</surname><given-names>F</given-names></name><name><surname>Josephson</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>JYC</given-names></name><name><surname>Pantel</surname><given-names>AR</given-names></name><name><surname>Cho</surname><given-names>SY</given-names></name><name><surname>Gage</surname><given-names>KL</given-names></name><name><surname>Piert</surname><given-names>M</given-names></name><name><surname>Iagaru</surname><given-names>A</given-names></name><name><surname>Pollard</surname><given-names>JH</given-names></name><name><surname>Wong</surname><given-names>V</given-names></name><name><surname>Jensen</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Stambler</surname><given-names>N</given-names></name><name><surname>Carroll</surname><given-names>PR</given-names></name><name><surname>Siegel</surname><given-names>BA</given-names></name><collab>CONDOR Study Group</collab></person-group><article-title>Diagnostic performance of</article-title><source>Results CONDOR Phase III Multicenter Study Clin Cancer Res</source><year>2021</year><volume>27</volume><issue>13</issue><fpage>3674</fpage><lpage>3682</lpage><pub-id pub-id-type="pmid">33622706</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, Wong JYC, Pantel AR, Cho SY, Gage KL, Piert M, Iagaru A, Pollard JH, Wong V, Jensen J, Lin T, Stambler N, Carroll PR, Siegel BA, CONDOR Study Group (2021) Diagnostic performance of. Results CONDOR Phase III Multicenter Study Clin Cancer Res 27(13):3674&#x02013;3682<pub-id pub-id-type="pmid">33622706</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Rowe</surname><given-names>SP</given-names></name><name><surname>Macura</surname><given-names>KJ</given-names></name><name><surname>Mena</surname><given-names>E</given-names></name><etal/></person-group><article-title>PSMA-based [</article-title><source>Mol Imaging Biol</source><year>2016</year><volume>18</volume><fpage>411</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1007/s11307-016-0957-6</pub-id><pub-id pub-id-type="pmid">27080322</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Rowe SP, Macura KJ, Mena E et al (2016) PSMA-based [. Mol Imaging Biol 18:411&#x02013;419<pub-id pub-id-type="pmid">27080322</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Rowe</surname><given-names>SP</given-names></name><name><surname>Pienta</surname><given-names>KJ</given-names></name><name><surname>Pomper</surname><given-names>MG</given-names></name><name><surname>Gorin</surname><given-names>MA</given-names></name><name><surname>PSMA-RADS</surname></name><name><surname>Version</surname></name></person-group><article-title>1.0: a step towards standardizing the interpretation and Reportingof PSMA-targeted PET imaging studies</article-title><source>EurUrol</source><year>2018</year><volume>73</volume><issue>4</issue><fpage>485</fpage><lpage>487</lpage></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Rowe SP, Pienta KJ, Pomper MG, Gorin MA, PSMA-RADS, Version (2018) 1.0: a step towards standardizing the interpretation and Reportingof PSMA-targeted PET imaging studies. EurUrol 73(4):485&#x02013;487</mixed-citation></citation-alternatives></ref><ref id="CR14"><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmuck</surname><given-names>S</given-names></name><name><surname>Mamach</surname><given-names>M</given-names></name><name><surname>Wilke</surname><given-names>F</given-names></name><name><surname>von Klot</surname><given-names>CA</given-names></name><name><surname>Henkenberens</surname><given-names>C</given-names></name><name><surname>Thackeray</surname><given-names>JT</given-names></name><name><surname>Sohns</surname><given-names>JM</given-names></name><name><surname>Geworski</surname><given-names>L</given-names></name><name><surname>Ross</surname><given-names>TL</given-names></name><name><surname>Wester</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Multiple time-point</article-title><source>Value Early Dynamic Delayed Imaging Clin Nucl Med</source><year>2017</year><volume>42</volume><fpage>286</fpage><lpage>293</lpage></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Schmuck S, Mamach M, Wilke F, von Klot CA, Henkenberens C, Thackeray JT, Sohns JM, Geworski L, Ross TL, Wester HJ et al (2017a) Multiple time-point. Value Early Dynamic Delayed Imaging Clin Nucl Med 42:286&#x02013;293</mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmuck</surname><given-names>S</given-names></name><name><surname>Nordlohne</surname><given-names>S</given-names></name><name><surname>von Klot</surname><given-names>CA</given-names></name><name><surname>Henkenberens</surname><given-names>C</given-names></name><name><surname>Sohns</surname><given-names>JM</given-names></name><name><surname>Christiansen</surname><given-names>H</given-names></name><name><surname>Wester</surname><given-names>HJ</given-names></name><name><surname>Ross</surname><given-names>TL</given-names></name><name><surname>Bengel</surname><given-names>FM</given-names></name><name><surname>Derlin</surname><given-names>T</given-names></name></person-group><article-title>Comparison of standard and delayed imaging to improve the detection rate of [</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2017</year><volume>44</volume><fpage>960</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1007/s00259-017-3669-5</pub-id><pub-id pub-id-type="pmid">28280856</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T (2017b) Comparison of standard and delayed imaging to improve the detection rate of [. Eur J Nucl Med Mol Imaging 44:960&#x02013;968<pub-id pub-id-type="pmid">28280856</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Harrison</surname><given-names>C</given-names></name><name><surname>Duan</surname><given-names>H</given-names></name><name><surname>Guja</surname><given-names>K</given-names></name><name><surname>Hatami</surname><given-names>N</given-names></name><name><surname>Franc</surname><given-names>BL</given-names></name><name><surname>Moradi</surname><given-names>F</given-names></name><name><surname>Aparici</surname><given-names>CM</given-names></name><name><surname>Davidzon</surname><given-names>GA</given-names></name><name><surname>Iagaru</surname><given-names>A</given-names></name></person-group><article-title>Prospective evaluation of</article-title><source>Focus Disease Localization Changes Manage J NuclMed</source><year>2020</year><volume>61</volume><issue>4</issue><fpage>546</fpage><lpage>551</lpage></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Song H, Harrison C, Duan H, Guja K, Hatami N, Franc BL, Moradi F, Aparici CM, Davidzon GA, Iagaru A (2020) Prospective evaluation of. Focus Disease Localization Changes Manage J NuclMed 61(4):546&#x02013;551</mixed-citation></citation-alternatives></ref><ref id="CR1"><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Trabulsi</surname><given-names>EJ</given-names></name><name><surname>Rumble</surname><given-names>RB</given-names></name><name><surname>Jadvar</surname><given-names>H</given-names></name><etal/></person-group><article-title>Optimum imaging strategies for advanced prostate cancer: ASCO Guideline</article-title><source>J Clin Oncol</source><year>2020</year><volume>38</volume><fpage>1963</fpage><lpage>1996</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.02757</pub-id><pub-id pub-id-type="pmid">31940221</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Trabulsi EJ, Rumble RB, Jadvar H et al (2020) Optimum imaging strategies for advanced prostate cancer: ASCO Guideline. J Clin Oncol 38:1963&#x02013;1996<pub-id pub-id-type="pmid">31940221</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Wondergem</surname><given-names>M</given-names></name><name><surname>van der Zant</surname><given-names>FM</given-names></name><name><surname>Knol</surname><given-names>RJJ</given-names></name><name><surname>Lazarenko</surname><given-names>SV</given-names></name><name><surname>Pruim</surname><given-names>J</given-names></name><name><surname>de Jong</surname><given-names>IJ</given-names></name></person-group><article-title>F-DCFPyL PET/CT in the detection of prostate Cancer at 60 and 120 minutes: detection rate, image quality, activity kinetics, and Biodistribution</article-title><source>J NuclMed</source><year>2017</year><volume>58</volume><issue>11</issue><fpage>1797</fpage><lpage>1804</lpage></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Wondergem M, van der Zant FM, Knol RJJ, Lazarenko SV, Pruim J, de Jong IJ (2017) F-DCFPyL PET/CT in the detection of prostate Cancer at 60 and 120 minutes: detection rate, image quality, activity kinetics, and Biodistribution. J NuclMed 58(11):1797&#x02013;1804</mixed-citation></citation-alternatives></ref></ref-list></back></article>